Pharma Journalist -

Werewolf Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate WTX-124, a conditionally activated…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab-rwlc) as the first adjuvant immunotherapy for adult patients with cutaneous…
Read More...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company focused on developing next-generation treatments for gout and tophaceous gout, has announced the successful closing of a…
Read More...

Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...

Milan-based biotech firm NanoPhoria Bioscience has announced the successful first close of its €83.5 million Series A funding round, marking a major step forward in its mission to…
Read More...

Oragenics, a clinical-stage biotech company focused on brain-targeted therapeutics, has announced a strategic collaboration with Receptor.AI, a drug profiling company leveraging…
Read More...

Affinia Therapeutics has announced the close of a $40 million Series C financing round to advance development of its lead gene therapy candidate, AFTX-201, for the treatment of BAG3…
Read More...

AstraZeneca and Daiichi Sankyo have announced breakthrough results from the Phase III TROPION-Breast02 trial, showing that their antibody drug conjugate Datroway (datopotamab…
Read More...

Chiesi Group and Arbor Biotechnologies have announced an exclusive global collaboration and licensing agreement to advance the development of innovative gene editing therapies for rare…
Read More...

Neurizon Therapeutics Limited has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001, a key step…
Read More...